# New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-es-22-006-new-approaches-for-incorporating-genetic-diversity-into/  
Official notice: https://www.grants.gov/search-results-detail/341632

> National Institutes of Health offered grants of up to $1.8 million to small businesses. Applications closed on November 8, 2022.

| Field | Value |
|---|---|
| Opportunity number | RFA-ES-22-006 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | November 8, 2022 |
| Award ceiling | $1.8 million |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.113 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed

## What the grant funds

This Funding Opportunity Announcement (FOA) supports Phase I (R43), Phase II (R44), Direct to Phase II (R44), and Fast Track (R44) Small Business Innovative Research (SBIR) grant applications from small businesses concerns (SBCs) to develop resources and approaches, including panels of cells or model organisms, that reflect the variability in human populations in chemical toxicity testing . Current toxicology testing is often limited to studies conducted in a small number of laboratory rodent strains, which can fail to identify clinically relevant toxicity if the conventional rodent strain is particularly resistant to the toxic effects of the test compound. Cost-effective screening systems with appropriate throughput are needed to better capture this variability in responses to chemical exposure in the population based on individual genetic susceptibility.

## Questions people ask

### Is RFA-ES-22-006 still open?

No. It closed on November 8, 2022.

### Who can apply for New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed)?

Closed November 8, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $1.8 million each.

### Who has been funded under RFA-ES-22-006?

NIH RePORTER lists 3 projects funded under RFA-ES-22-006 in fiscal 2023 to 2024, at 3 institutions. The most were at Vivoverse, LLC, Litron Laboratories, LTD., Nortis, Inc.

### Who has won Environmental Health grants before?

The largest recipients over five fiscal years were Icahn School of Medicine at Mount Sinai, The Trustees of Columbia University in the City of New York, University of North Carolina at Chapel Hill. The program made 1,980 awards worth $2.1 billion in that time.